TCRT · Alaunos Therapeutics, Inc. · Analyst Estimates
$1.74
-0.10 (-5.43%)
At close · Nov 6
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.42M
Shares
2.54M
Volume · Nov 6
101.46K
Avg daily vol (3M)
7.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Alaunos Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 03:53 UTC · Publication dates shown per estimate · 2 metric / period groups
FY ending 2024-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0.00
|
0.00
|
0.00
|
0
|
Q ending 2024-06-30
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0.00
|
0.00
|
0.00
|
0
|
Key facts
CIK
1107421
CUSIP
98973P309
13F (30d)
18 filings
11 filers
Visit website
Investor relations